Mierin

Ezetimibe

Primary hypercholesterolemia in combination w/ an HMG-CoA reductase inhibitor (statin) or as monotherapy as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low density lipoprotein cholesterol (LDL-C), Apo B, & triglycerides (TG) & to increase high-density lipoprotein cholesterol (HDL-C) in patients w/ primary (heterozygous familial & non-familial) hypercholesterolemia. In combination w/ fenofibrate as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, & non-HDL-C in patients w/ mixed hyperlipidemia. Homozygous familial hypercholesterolemia (HoFH) in combination w/ statin for the reduction of elevated total-C & LDL-C levels in patients w/ HoFH.

10 mg once daily used alone, w/ statin or w/ fenofibrate at any time of the day. Co-administration w/ bile sequestrant: Ezetimibe should be taken either ≥2 hr before or ≥4 hr after administration of bile acid sequestrants.

May be taken with or without food.

Patient should be on appropriate lipid-lowering diet & should continue on this diet during treatment. Not recommended in patients w/ moderate (Child Pugh score 7-9) or severe (Child Pugh score >9) liver dysfunction. Not recommended in childn <10 yr.

Dyslipidaemic Agents

C10AX09 - ezetimibe ; Belongs to the class of other lipid modifying agents.

G